状腺多巴胺功能和运动减缓在基本震加上基本震
Aino M Kuusela1,2, Emma A Honkanen1,2, Elina Jaakkola1,2,3,4
1Clinical Neurosciences, University of Turku, Turku, Finland.
Movement disorders clinical practice
|December 23, 2024
概括
基本震加 (ET+) 显示微妙的条纹性多巴胺功能障碍,与布拉迪基尼西亚和震不对称有关. 这表明ET+患者的部分多巴胺作用机制,使其与帕金森病不同.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 放射学 放射学是一门学科.
背景情况:
- 基本震 (ET) 通常显示正常的条纹性多巴胺转运体 (DAT) 结合.
- 新出现的证据表明ET中存在部分多巴胺作用机制,特别是在具有额外神经症状 (ET+) 的ET患者中.
- 在ET和帕金森病 (PD) 之间存在流行病学联系.
研究的目的:
- 研究ET+中多巴胺基病理生理学的研究.
- 将ET+中的多巴胺功能与帕金森病 (PD) 进行比较.
主要方法:
- [123I]FP-CIT SPECT成像和临床检查对43名ET+患者,115名PD患者和40名健康对照进行.
- 诊断确认后的中位数随访时间为3.0年.
- 延长ET+患者的随访时间 (平均7.7年).
- 区域特异性条状DAT结合比率与MDS-UPDRS电机分数进行了比较和相关联.
主要成果:
- 在ET+和PD两组中,布拉迪基尼西亚得分与后门DAT结合负相关.
- 布拉迪基尼西亚和DAT结合之间最强的相关性是在手指敲击中观察到的.
- 在ET+患者中,动力震不对称与后骨DAT结合不对称相关,表明微妙的对侧DAT损失与更严重的震.
结论:
- 在ET+中微妙的布拉迪基尼西亚与条状多巴胺功能障碍相关.
- ET+中的动力震不对称性与半球DAT结合不对称性有关.
- 这些发现支持ET+病理生理学中的部分多巴氨基参与.
关键词:
帕金森病的疾病.基本震是一种基本的震.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,更多相关视频
相关概念视频
Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
614
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
614
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
253
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
253
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K


